Form 4: Zevra Therapeutics Director John B. Bode Acquires 10,000 Shares

Director John B. Bode of Zevra Therapeutics, Inc. purchased 10,000 shares of common stock at an average price of $7.9624 on March 19, 2025.

Summary

• On March 19, 2025, John B. Bode, a director of Zevra Therapeutics, Inc., acquired 10,000 shares of common stock.
• The purchase was made at a weighted average price of $7.9624 per share.
• The prices for individual transactions ranged from $7.91 to $8.00.
• Following the transaction, Mr. Bode directly owns 40,000 shares.
• This transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the purchase is relatively small and may not be highly significant.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or any individuals owning more than 10% of a company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholders, as it may signal confidence from a company director.

Key Dates

Keywords

Form 4, ZEVRA THERAPEUTICS, ZVRA, insider trading, stock acquisition, John B. Bode, director